BioLineRx Stock Rating Reaffirmed by HC Wainwright - Defense World

BLRX Stock  ILS 7.70  0.40  4.94%   
About 62% of BioLine RX's investor base is looking to short. The analysis of current outlook of investing in BioLine RX suggests that many traders are alarmed regarding BioLine RX's prospects. The current market sentiment, together with BioLine RX's historical and current headlines, can help investors time the market. In addition, many technical investors use BioLine RX stock news signals to limit their universe of possible portfolio assets.
  
BioLineRx Stock Rating Reaffirmed by HC Wainwright Defense World

Read at news.google.com
Google News at Macroaxis
  

BioLine RX Fundamental Analysis

We analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

BioLine RX is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

BioLine RX Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLine RX stock to make a market-neutral strategy. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics with similar companies.

Complementary Tools for BioLine Stock analysis

When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance